Skip to content.

Moderna Inc. and Novocol Pharma announce fill-finish agreement for mRNA vaccines manufactured in Canada

Date Announced

May 4, 2023

Lead Office


On May 4, 2023, Moderna, Inc. ("Moderna") announced its long-term agreement with Novocol Pharma to perform fill-finish labelling and packaging of Canadian-made mRNA vaccines. Fill-finish sterile manufacturing is the last step in the vaccine production cycle that involves transferring the vaccine into vials and packaging. This agreement results in the fill-finish capacity of Moderna vaccines manufactured at its Laval-based mRNA facility, which is anticipated to open at the end of 2024.

Moderna is a pharmaceutical and biotechnology company that focuses on RNA therapeutics, headquartered in Cambridge, Massachusetts.

Novocol Pharma is a leading sterile injectable contract development and manufacturing organization, headquartered in Cambridge, Ontario.

McCarthy Tétrault advised Moderna with a team led by Philippe Leclerc and Véronique Wattiez Larose.